Storage of blood components

Current Opinion in Hematology

Volumn 6, Issue 6, 1999, Pages 427-431

  Högman, Claes F ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

APHERESIS; ARTICLE; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BLOOD TRANSFUSION REACTION; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; PRIORITY JOURNAL; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION;

BLOOD PRESERVATION; BLOOD TRANSFUSION; HUMANS;

EID: 0032719423     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199911000-00013     Document Type: Article

References (41)

1. 1 Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. and the Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group: A multicenter, randomized, controlled clinical trial of transfusion requirements. N Engl J Med 1999, 340:409-417. A restrictive strategy of red-cell transfusion is at least as effective as and possibly superior to a liberal transfusion strategy in critically ill patients, with the possible exception of patients with acute myocardial infarction and unstable angina.
2. 2 van de Watering LMG, Hermans J, Houbiers JGA: Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998, 97:562-568.
3. 3 Tartter PI, Mohandas K, Azar P, Endres J, Kaplan J, Spivack M: Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998, 176:462-466.
4. 4 Houbiers JG, van de Velde CJ, van de Watering LM, Hermans J, Schreuder S, Bijnen AB, et al.: Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion 1997, 37:126-134.
5. 5 Fitzgerald RD, Martin CM, Dietz GE, Doig GS, Potter RF, Sibbald WJ: Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit Care Med 1997, 25:726-732.
6. 6 Kimura H, Hamasaki N, Yamamoto M, Tomonaga M: Circulation of red blood cells having high levels of 2,3-bisphosphoglycerate protects rat brain from ischemic metabolic changes during hemodilution. Stroke 1995, 26:1431-1437.
7. 7 Högman CF, de Verdier C-H, Borgström L: Studies on the mechanism of human red cell loss of viability during storage at +4°C. II. Relation between cellular morphology and viability. Vox Sang 1987, 52:20-23.
8. 8 Nielsen HJ: Clinical impact of bioactive substances in blood components: implications for leukocyte filtration. Infusionsther Transfusionsmed 1998, 25:296-304. Complications and adverse reactions related to transfusion with blood components appear to be dependent on storage time and content of various leukocyte-derived and platelet-derived bioactive substances. Although leukocyte depletion may improve clinical outcome, the optimal timing and indications and the cost-effectiveness of leukocyte depletion has not been fully resolved.
9. 9 Högman CF: Preparation and preservation of red cells. Vox Sang 1998, 74(suppl 2):177-187. Most of the methods for the preparation and storage of red cells allow 35-42 days of storage with a mean in vivo recovery of > 75%. However, the content of erythrocyte 2,3-DPG is commonly lost within 1-2 weeks, caused by accumulation of acid metabolites, but can be maintained longer with new systems of storage. Leukodepletion of red cells by filtration is used increasingly, but its importance in the majority of transfusions is still unclear. New options for the preparation and storage of erythrocytes are available and undergo continuous evaluation.
10. 10 Mincheff MS, Meryman HT, Kapoor V, Alsop P, Wotzel M: Blood transfusion and immunomodulation: a possible mechanism. Vox Sang 1993, 65:18-24.
11. 11 Sibinga C: Immune effects of blood transfusion. Curr Opin Hematol 1999, 6:442-445.
12. 12 Frabetti F, Musiani D, Marini M, Fanelli C, Coppola S, Ghibelli L, et al.: White cell apoptosis in packed red cells. Transfusion 1998, 38:1082-1089.
13. 13 Mincheff M, Loukinov D, Zoubak S, Hammett M, Meryman H: Fas and Fas ligand expression on human peripheral blood leukocytes. Vox Sang 1998, 74:113-121. Human peripheral blood granulocytes, monocytes, and natural killer cells contain intracellular presynthesized Fas-L, which they readily express following blood anticoagulation, blood storage, or cell separation. Soluble Fas-L is released from those cells and can be detected in protein-free supernatants by immunoblotting.
14. 14 Müller-Steinhardt M, Kirchner H, Klüter H: Impact of storage at 22°C and citrate anticoagulation on the cytokine secretion of mononuctear leukocytes. Vox Sang 1998, 75:12-17. Storage of peripheral blood mononuclear cells at 22°C with CPD leads to an impaired cytokine response, but peripheral blood mononuclear cells are still capable of secreting cytokines after 5 days of storage.
15. 15 Högman CF, Meryman HT: Storage parameters affecting RBC survival and function following transfusion. Transfus Med Rev 1999, 13. This is an extensive review summarizing new and old data which influence the viability and function of erythrocytes during storage at 4°C.
16. 16 Högman CF, Eriksson L, Wallvik J, Payrat JM: Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5CPD Erythro-Sol Opti System. Vox Sang 1997, 73:212-219.
17. 17 Högman CF, Knutson F, Lööf H: Storage of whole blood before separation: the effect of temperature on red cell 2,3 DPG and the accumulation of lactate. Transfusion 1999, 39:492-497.
18. 18 Solheim BG, Bergerud UE, Kjeldsen-Kragh J, Brosstad F, Mollnes TE, Högman CF, Eriksson L, Schutz R: Improved blood preservation with 0.5CPD Erythro-Sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood. Vox Sang 1998, 74:168-175. Red cell 2,3-DPG decreased to about half of normal concentration in 0.5 CPD blood after 24 hours at 20°C before component separation. During storage in Erythro-Sol at 4*C 2,3-DPG increased to normal or slightly supernormal levels in one-third of the units, in others maintained at the initial level for 2 to 4 weeks before gradual decay to an average of 39% at 48 days. In citrate-phosphate-dextrose-sodium chloride-adenine-glucose-mannitol (CPD-SAGM) controls, low initial concentrations and rapid decrease were observed.
19. 19 Zeiler TA, Kretschmer V: Automated blood component collection with the MCS-3p cell separator: evaluation of three protocols for buffy coat-poor and white cell-reduced packed red cells and plasma. Transfusion 1997, 37:791-797.
20. 20 Holme S, Dean Elfath M, Whitley P: Evaluation of in vivo and in vitro quality of apheresis-collected RBC stored for 42 days. Vox Sang 1998, 75:212-217. Erythrocyte units collected by apheresis demonstrated low variability in volume of erythrocyte mass collected, and showed similar erythrocyte properties as compared to manually collected erythrocytes after processing and after 42 days of storage.
21. 21 Heaton WAL, Rebulla P, Pappalettera M, Dzik WH: A comparative analysis of different methods for routine blood component preparation. Transfus Med Rev 1997, 11:116-129.
22. 22 Palmer DS, Aye MT, Dumont L, Dumont D, McCombie N, Giulivi A, et al.: Prevention of cytokine accumulation in platelets obtained with the COBE spectra apheresis system. Vox Sang 1998, 75:115-123. Leukocyte levels in PCs collected with the COBE Spectra Apheresis System (Cobe BCT, Lakewood, Colorado, USA) are sufficiently low to limit cytokine production during 7 days of storage.
23. 23 Heddle NM: Febrile nonhemolytic transfusion reactions to platelets. Curr Opin Hematol 1995, 2:478-483.
24. 24 Oksanen K, Ebeling F, Kekomäki R, Elonen E, Sahlstedt L, Volin L, et al.: Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 1994, 67:356-361.
25. 25 Högman CF, Berséus O, Eriksson L, Gulliksson H: Buffy-coat-derived platelet concentrates: Swedish experience. Transfus Sci 1997, 18:3-13.
26. 26 Eriksson L, Eriksson G, Högman CF: Storage of buffy coat preparations at 22°C in plastic containers with different gas permeability. Vox Sang 1997, 73:74-80.
27. 27 Edvardsen L, Taaning E, Mynster T, Hvolris J, Drachman O, Nielsen HJ: Bioactive substances in buffy-coat-derived platelet pools stored in platelet-additive solutions. Brit J Haematol 1998, 103:445-448.
28. 28 Shimizu T, Murphy S: Roles of acetate and phosphate in the successful storage of platelet concentrates prepared with an acetate-containing additive solution. Transfusion 1993, 33:304-310.
29. 11/U).
30. 30 Hume HA, Popovski MA, Benson K, Glassman AB, Hines D, Oberman HA, et al.: Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion 1996, 36:904-909.
31. 31 Yenicesu I, Tezcan I, Tuncer AM: Hypotensive reactions during platelet transfusions. Transfusion 1998, 38:410.
32. 32 Sweeney JD, Dupuis M, Mega AJ: Hypotensive reactions to red cells filtered at the bedside, but not to those filtered before storage, in patients taking ACE inhibitors. Transfusion 1998, 38:410-411.
33. 33 Abe H, Ikebuchi K, Shimbo M, Sekiguchi S: Hypotensive reactions with a white cell-reduction filter: activation of kallikrein-kinin cascade in a patient. Transfusion 1998, 38:411-412.
34. 34 Belloni M, Alghisi A, Bettini C, Soli M, Zampieri L: Hypotensive reactions associated with white cell-reduced apheresis platelet concentrates in patients not receiving ACE inhibitors. Transfusion 1998, 38:412-413.
35. 35 Hume H, Popovsky MA, Anderson K, Oberman HA, Benson K: Comments to reports in ref. 24-27. Transfusion 1998, 38:413-415. The authors conclude that it is highly unlikely that all transfusion reactions characterized predominantly by hypotension are caused by a single factor or group of factors. Nevertheless, the reports published to date suggest that bradykinin may play a role in some of these reactions, possibly through a combination of increased generation and decreased metabolism and/or some as yet undefined component, donor, and/or recipient factors.
36. 36 Hild M, Söderström T, Egberg N, Lundahl J: Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrates. Vox Sang 1998, 75:18-25.
37. 37 Gong J, Högman CF, Lundholm M, Gustafsson I: Novel automated microbial screening of platelet concentrates. APMIS 1994, 102:72-78.
38. 38 Blajchman MA: Bacterial contamination and proliferation during the storage of cellular blood products. Vox Sang 1998, 74(Suppl 2):155-159. The presence of bacteria in cellular blood products is a more frequent event than has been appreciated heretofore. Transfusion-associated septic reactions due to contaminated platelet concentrates are much more common than those due to red cell concentrates, even though it is likely that the frequency of bacterial contamination is the same in both.
39. 39 Boulton FE, Chapman ST, Walsh TH: Fatal reaction to transfusion of red-cell concentrate contaminated with Serratia liquefaciens. Transfus Med 1998, 8:15-18. Case report of a fatal transfusion reaction caused by a 19-day-old unit of sodium chloride-adenine-glucose-mannitol additive solution-suspended erythrocytes contaminated with Serratia liquefaciens. The patient died from endotoxic shock.
40. 40 McDonald CP, Hartley S, Orchard K, Hughes G, Brett MM, Hewitt PE, Barbara JAJ: Fatal Clostridium perfringens sepsis from a pooled platelet transfusion. Transfus Med 1998, 8:19-22. Case report of a fatal transfusion reaction caused by a pooled platelet preparation from 4 buffy coats given on day 5 from blood collection. The responsible microorganism was shown to be Clostridium perfringens. This microorganism was subsequently cultured from the skin of the donor at venipuncture site. The donor, a father of two children, 3 years and 16 months old, used to change nappies and carry the children in the crook of his arm. This contact could explain the fecal contamination of his lower arm.
41. 41 Högman CF, Engstrand L: Serious bacterial complications from blood components - how do they occur? [Editorial] Transfus Med 1998, 8:1-3. As a comment to the two case reports [38,39] it is concluded that the properties of the microorganisms which contaminate blood components seem to be determinants of the seriousness of the reaction, particularly the capacity of the microorgansms to multiply and form toxins under the storage conditions applied.